韩新增406新冠确诊 今起启动疫苗接种
据《韩联社》报道,韩国中央防疫对策本部公布,截至26日凌晨,新增406宗确诊新冠肺炎个案,其中382宗属本地感染。累计增至8.89万宗。死亡个案增4宗,至1,585宗。
当地今起开启新冠病毒疫苗接种工作全国的卫生所、疗养医院等1,915处接种点从当天上午9点起为优先接种对象施打阿斯利康疫苗。SK生物科技公司安东工厂受阿斯利康委托生产这批疫苗。政府与阿斯利康签订1,000万人份疫苗的采购合同,其中第一批78.5万人份已从24日起陆续交付。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.